Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest amnestic mild cognitive impairment Stories

2012-08-07 10:26:29

VANCOUVER, Aug. 7, 2012 /PRNewswire/ - Allon Therapeutics Inc. (TSX: NPC) today announced its unaudited operating results for the three and six-month periods ended June 30, 2012. Allon also said that its successful $10 million equity financing completed during the second quarter and ongoing progress in its pivotal clinical trial have kept the Company on track to achieve its objective of securing marketing approval for its lead neuroprotective drug candidate davunetide as a treatment...

2012-02-02 18:00:31

It can be difficult to distinguish between people with normal age-associated memory loss and those with amnestic mild cognitive impairment (aMCI). However people with aMCI are at a greater risk of developing Alzheimer's disease (AD), and identification of these people would mean that they could begin treatment as early as possible. New research published in BioMed Central's open access journal BMC Geriatrics shows that specific questions, included as part of a questionnaire designed to help...

2010-08-26 11:19:00

NEW YORK, Aug. 26 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant of $240,000 to AgeneBio Inc. to develop a new class of small-molecules that have promise in treating amnestic mild cognitive impairment (aMCI), a neurological condition that often progresses to Alzheimer's disease and affects more than 3 million aging Americans. Approximately fifteen percent of aMCI patients progress to an Alzheimer's disease (AD)...

2008-07-30 12:00:21

CHICAGO, ILLINOIS--(Marketwire - July 30, 2008) - Allon Therapeutics Inc. (TSX:NPC) - Clinical trial data presented today to two scientific workshops at the International Conference on Alzheimer's Disease and Related Disorders (ICAD 2008) validate the therapeutic potential of addressing the "tangles" component of the classic Alzheimer's "plaques and tangles" pathology. The data from a clinical trial evaluating drug candidate AL-108 in 144 patients with amnestic mild cognitive impairment...

2008-07-28 15:00:22

CHICAGO, ILLINOIS--(Marketwire - July 28, 2008) - Allon Therapeutics Inc. (TSX:NPC) - A potential new treatment for Alzheimer's disease that reduces the classic Alzheimer's "tangle" pathology in mice has also improved specific memory function in humans with amnestic mild cognitive impairment (aMCI), a precursor to Alzheimer's disease, according to a presentation today at a news conference hosted by the Alzheimer's Association at their International Conference on Alzheimer's Disease and...